Clinical features and outcomes of patients with colorectal cancers harboring NRAS mutations

PURPOSE: NRAS mutations are now routinely included in RAS testing prior to EGFR (epidermal growth factor receptor) inhibitor therapy for metastatic colorectal cancer (mCRC). The clinical implications of NRAS mutation beyond lack of response to anti-EGFR therapy, however, are not known. We undertook...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Main Authors: Cercek, Andrea, Braghiroli, Maria Ignez, Chou, Joanne F., Hechtman, Jaclyn F., Kemeny, Nancy, Saltz, Leonard, Capanu, Marinela, Yaeger, Rona
Formato: Artigo
Idioma:Inglês
Publicado: 2017
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5788017/
https://ncbi.nlm.nih.gov/pubmed/28446505
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-0400
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares